Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2015

View Archived Issues

Ebola vaccine based on the 2014 Zaire Guinea epidemic strain: Phase I clinical data

First preclinical data on Boehringer Ingelheim's novel MEK/Aurora kinase inhibitor

Pfizer reflects on achievements of first quarter 2015

EMA grants orphan drug designation to EspeRare's rimeporide for DMD

Braeburn acquires two new schizophrenia therapies

Preclinical findings with ADC BAY-1187982 lead to clinical study

Preliminary phase III results of Civacir to prevent HCV reinfection in liver transplant patients

Theraclone Sciences to screen antibodies from survivors of Ebola virus infection

Singulex and Dutch Technology Foundation launch Biomarker Development Center

Anti-CD73 MAb enhances antitumor activity of anti-PD-1 treatment

Sichuan Haisco Pharmaceutical discloses FXa inhibitors

Acetylon Pharmaceuticals patents HDAC inhibitors

Boehringer Ingelheim reports development of GlyT-1 inhibitors

Merck & Co. describes new Fc-containing polypeptides

Lilly presents novel NAMPT inhibitors

CytoDyn submits full phase III protocol to FDA for PRO-140 in HIV

Cypher Genomics and University of Pennsylvania to research genetic factors in PSP

Retrophin's RE-024 receives U.S. orphan drug designation for PKAN

Tenapanor fails to significantly reduce albuminuria in patients with CKD and type 2 diabetes

NCI launches phase III trial testing strategies for prevention of anal cancer

Primary endpoint met in phase IIb study of clazakizumab for rheumatoid arthritis

Teva reiterates proposal to acquire Mylan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.